[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Levothyroxine.]
[A14AA02, stanozolol, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Stanozolol.]
[A02BX02, sucralfate, Sucralfate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Levothyroxine.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Levothyroxine.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Levothyroxine.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be decreased when used in combination with Levothyroxine.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be decreased when used in combination with Levothyroxine.]
[L01BB02, mercaptopurine, Levothyroxine may increase the excretion rate of Mercaptopurine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BA01, tamoxifen, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Tamoxifen.]
[R03CC03, terbutaline, The risk or severity of adverse effects can be increased when Terbutaline is combined with Levothyroxine.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be decreased when it is combined with Levothyroxine.]
[G03BA03, testosterone, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Testosterone.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Levothyroxine.]
[R03DA07, theobromine, Levothyroxine may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, Levothyroxine may increase the excretion rate of Theophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01ED01, timolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Timolol.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be decreased when used in combination with Levothyroxine.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Levothyroxine.]
[N06AX05, trazodone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Trazodone.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Levothyroxine.]
[S01BA05, triamcinolone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Triamcinolone.]
[R03BA07, mometasone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Mometasone.]
[N03AC02, trimethadione, The metabolism of Trimethadione can be decreased when combined with Levothyroxine.]
[N06AA06, trimipramine, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Trimipramine.]
[L01EX04, vandetanib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Vandetanib.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be decreased when used in combination with Levothyroxine.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Levothyroxine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be decreased when it is combined with Levothyroxine.]
[L01CA02, vincristine, The serum concentration of Vincristine can be decreased when it is combined with Levothyroxine.]
[B01AA03, warfarin, The therapeutic efficacy of Warfarin can be increased when used in combination with Levothyroxine.]
[J05AF01, zidovudine, The metabolism of Levothyroxine can be increased when combined with Zidovudine.]
[J05AE02, indinavir, The metabolism of Levothyroxine can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Vemurafenib.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be decreased when it is combined with Levothyroxine.]
[L01ED01, crizotinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Crizotinib.]
[A02BC04, rabeprazole, Rabeprazole can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01XX02, asparaginase, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Asparaginase Escherichia coli.]
[N02BA01, aspirin, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ruxolitinib.]
[C07AB03, atenolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Atenolol.]
[L01EK01, axitinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Axitinib.]
[H02AB11, prednylidene, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Prednylidene.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be decreased when it is combined with Levothyroxine.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be decreased when it is combined with Levothyroxine.]
[L02BB04, enzalutamide, The metabolism of Enzalutamide can be decreased when combined with Levothyroxine.]
[L01EA04, bosutinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Bosutinib.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C01CA18, octopamine, Levothyroxine may increase the vasoconstricting activities of Octopamine.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EX05, regorafenib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Regorafenib.]
[J05AE04, nelfinavir, The metabolism of Levothyroxine can be increased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be decreased when it is combined with Levothyroxine.]
[L01EX07, cabozantinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Cabozantinib.]
[L01EA05, ponatinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ponatinib.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Levothyroxine.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be decreased when used in combination with Levothyroxine.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be decreased when it is combined with Levothyroxine.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levothyroxine.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Levothyroxine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be decreased when used in combination with Levothyroxine.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Levothyroxine.]
[M01AH01, celecoxib, The metabolism of Celecoxib can be decreased when combined with Levothyroxine.]
[N02CC02, naratriptan, Levothyroxine may increase the vasoconstricting activities of Naratriptan.]
[C10AC04, colesevelam, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Colesevelam.]
[L04AA18, everolimus, The serum concentration of Everolimus can be decreased when it is combined with Levothyroxine.]
[L01EC02, dabrafenib, The serum concentration of Dabrafenib can be decreased when it is combined with Levothyroxine.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Levothyroxine.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EB03, afatinib, The serum concentration of Afatinib can be decreased when it is combined with Levothyroxine.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Levothyroxine.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Levothyroxine.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Levothyroxine.]
[A05AA03, cholic acid, The excretion of Cholic Acid can be decreased when combined with Levothyroxine.]
[L01EL01, ibrutinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Levothyroxine.]
[J05AP05, simeprevir, The excretion of Simeprevir can be decreased when combined with Levothyroxine.]
[V03AE05, sucroferric oxyhydroxide, The serum concentration of Levothyroxine can be decreased when it is combined with Iron sucrose.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be decreased when it is combined with Levothyroxine.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Levothyroxine.]
[C01CA27, droxidopa, The therapeutic efficacy of Droxidopa can be increased when used in combination with Levothyroxine.]
[C07AB04, acebutolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Acebutolol.]
[S03BA03, betamethasone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Betamethasone.]
[S01ED02, betaxolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Betaxolol.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be decreased when used in combination with Levothyroxine.]
[L01ED02, ceritinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ceritinib.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Levothyroxine.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levothyroxine.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Levothyroxine.]
[V03AE01, polystyrene sulfonate, Tolevamer can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Levothyroxine.]
[L01EX09, nintedanib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Nintedanib.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AP09, dasabuvir, The metabolism of Levothyroxine can be decreased when combined with Dasabuvir.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Levothyroxine.]
[N06AX11, mirtazapine, The risk or severity of adverse effects can be increased when Levothyroxine is combined with Mirtazapine.]
[L01EX08, lenvatinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Lenvatinib.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be decreased when it is combined with Levothyroxine.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Levothyroxine.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be decreased when used in combination with Levothyroxine.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Levothyroxine.]
[B02BC05, adrenalone, Levothyroxine may increase the vasoconstricting activities of Adrenalone.]
[A02BC03, lansoprazole, Lansoprazole can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EB04, osimertinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Osimertinib.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Levothyroxine.]
[L01EE02, cobimetinib, The serum concentration of Cobimetinib can be decreased when it is combined with Levothyroxine.]
[L01ED03, alectinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Alectinib.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Levothyroxine.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Levothyroxine.]
[J05AP11, grazoprevir, The excretion of Grazoprevir can be decreased when combined with Levothyroxine.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA02, aloxiprin, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Aloxiprin.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be decreased when it is combined with Levothyroxine.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Levothyroxine.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AA19, amineptin, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Amineptine.]
[C07AA19, bupranolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Levothyroxine.]
[M02AA03, clofezone, Rabeprazole can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Levothyroxine.]
[A07EC04, balsalazide, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Balsalazide.]
[R03DA08, bamifylline, Levothyroxine may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BC01, caffeine, Levothyroxine may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be decreased when used in combination with Levothyroxine.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04BA03, calcium chloride, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium chloride.]
[J05AE09, tipranavir, The metabolism of Levothyroxine can be increased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium gluconate.]
[A12AA01, calcium phosphate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium Phosphate.]
[L01EX10, midostaurin, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Midostaurin.]
[L01ED04, brigatinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Brigatinib.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Levothyroxine.]
[L01EH02, neratinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Levothyroxine.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be decreased when it is combined with Levothyroxine.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be decreased when it is combined with Levothyroxine.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Levothyroxine can be increased when combined with Efavirenz.]
[C07AA17, bopindolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Bopindolol.]
[L01EL02, acalabrutinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Acalabrutinib.]
[J05AX18, letermovir, The excretion of Letermovir can be decreased when combined with Levothyroxine.]
[N06AA15, butriptyline, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Levothyroxine may increase the excretion rate of Acetyldigoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ06, semaglutide, The serum concentration of Levothyroxine can be increased when it is combined with Semaglutide.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Levothyroxine.]
[C01CX09, angiotensin II, Levothyroxine may increase the vasoconstricting activities of Angiotensin II.]
[L02BB05, apalutamide, The metabolism of Apalutamide can be decreased when combined with Levothyroxine.]
[N03AF01, carbamazepine, The protein binding of Levothyroxine can be decreased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium polycarbophil.]
[C07AG02, carvedilol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Carvedilol.]
[B02BX09, fostamatinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fostamatinib.]
[V03AE10, sodium zirconium cyclosilicate, Sodium zirconium cyclosilicate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be decreased when it is combined with Levothyroxine.]
[C07AB08, celiprolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Levothyroxine.]
[L01EB07, dacomitinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Dacomitinib.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be decreased when used in combination with Levothyroxine.]
[R03DA02, oxtriphylline, Levothyroxine may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be decreased when it is combined with Levothyroxine.]
[R03BB08, revefenacin, Levothyroxine may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01EX12, larotrectinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Larotrectinib.]
[L01EX13, gilteritinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Levothyroxine.]
[L01EN01, erdafitinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Erdafitinib.]
[H02AB14, cloprednol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Cloprednol.]
[V03AE07, calcium acetate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium acetate.]
[V03AE02, sevelamer, The serum concentration of Levothyroxine can be decreased when it is combined with Sevelamer.]
[H02AB17, cortivazol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Cortivazol.]
[L01EX15, pexidartinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Pexidartinib.]
[L01EJ02, fedratinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fedratinib.]
[L01EX14, entrectinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Entrectinib.]
[J01XX12, lefamulin, Levothyroxine may increase the excretion rate of Lefamulin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Levothyroxine.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be decreased when used in combination with Levothyroxine.]
[H02AB13, deflazacort, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Deflazacort.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be decreased when it is combined with Levothyroxine.]
[G03AC09, desogestrel, The metabolism of Levothyroxine can be increased when combined with Desogestrel.]
[L01EX18, avapritinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Avapritinib.]
[C10AX15, bempedoic acid, The excretion of Bempedoic acid can be decreased when combined with Levothyroxine.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Levothyroxine.]
[L01EE04, selumetinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Selumetinib.]
[V03AE03, lanthanum carbonate, Lanthanum carbonate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EH03, tucatinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Tucatinib.]
[L01EX17, capmatinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Capmatinib.]
[D07XB03, fluprednidene, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluprednidene.]
[L01EX22, selpercatinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Selpercatinib.]
[L01FX15, belantamab mafodotin, The excretion of Belantamab mafodotin can be decreased when combined with Levothyroxine.]
[P01BA01, chloroquine, The metabolism of Chloroquine can be decreased when combined with Levothyroxine.]
[G03CA06, chlorotrianisene, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Chlorotrianisene.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Levothyroxine.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Levothyroxine.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Choline salicylate.]
[M02AA06, etofenamate, The therapeutic efficacy of Etofenamate can be increased when used in combination with Levothyroxine.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be decreased when it is combined with Levothyroxine.]
[L02BX04, relugolix, The serum concentration of Relugolix can be decreased when it is combined with Levothyroxine.]
[L01EX21, tepotinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Tepotinib.]
[N06BA10, fenethylline, Levothyroxine may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA08, fenozolone, The risk or severity of adverse effects can be increased when Fenozolone is combined with Levothyroxine.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, The serum concentration of Levothyroxine can be decreased when it is combined with Iron sucrose.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be decreased when used in combination with Levothyroxine.]
[L01EK03, tivozanib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Tivozanib.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, Cimetidine can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EN03, infigratinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Infigratinib.]
[S03AA07, ciprofloxacin, Ciprofloxacin can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AB04, citalopram, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Citalopram.]
[C03DA05, finerenone, The metabolism of Finerenone can be decreased when combined with Levothyroxine.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Levothyroxine.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be decreased when used in combination with Levothyroxine.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be decreased when used in combination with Levothyroxine.]
[R03CC13, clenbuterol, The risk or severity of adverse effects can be increased when Clenbuterol is combined with Levothyroxine.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium glubionate anhydrous.]
[L01EA06, asciminib, The metabolism of Levothyroxine can be decreased when combined with Asciminib.]
[C10AB01, clofibrate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Levothyroxine can be increased when combined with Mitapivat.]
[L01EJ03, pacritinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Clomipramine.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Levothyroxine.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Levothyroxine.]
[A02BC08, vonoprazan, Vonoprazan can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA56, deucravacitinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Deucravacitinib.]
[J05AX31, lenacapavir, The serum concentration of Lenacapavir can be decreased when it is combined with Levothyroxine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be decreased when it is combined with Levothyroxine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be decreased when used in combination with Levothyroxine.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Levothyroxine.]
[S02DA02, cocaine, Levothyroxine may increase the vasoconstricting activities of Cocaine.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be decreased when used in combination with Levothyroxine.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be decreased when used in combination with Levothyroxine.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Levothyroxine.]
[R03BA08, ciclesonide, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Ciclesonide.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Levothyroxine.]
[L01EA01, imatinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Imatinib.]
[A02BC05, esomeprazole, Esomeprazole can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N03AX09, lamotrigine, The metabolism of Levothyroxine can be increased when combined with Lamotrigine.]
[S01BA03, cortisone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Cortisone.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A08AA09, mefenorex, The risk or severity of adverse effects can be increased when Mefenorex is combined with Levothyroxine.]
[C07AA14, mepindolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Meprednisone.]
[R03CB02, methoxyphenamine, The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Levothyroxine.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be decreased when used in combination with Levothyroxine.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Levothyroxine.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be decreased when it is combined with Levothyroxine.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be decreased when it is combined with Levothyroxine.]
[G03XA01, danazol, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Danazol.]
[M03CA01, dantrolene, The therapeutic efficacy of Dantrolene can be increased when used in combination with Levothyroxine.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Levothyroxine.]
[C07AB12, nebivolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Nebivolol.]
[N06AX06, nefazodone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Nefazodone.]
[C01CA23, theodrenaline, The therapeutic efficacy of Theodrenaline can be increased when used in combination with Levothyroxine.]
[N06AB10, escitalopram, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Escitalopram.]
[A07EC03, olsalazine, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Olsalazine.]
[N06AA01, desipramine, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Desipramine.]
[L01EB01, gefitinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of adverse effects can be increased when Amphetamine is combined with Levothyroxine.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Levothyroxine.]
[N06AB05, paroxetine, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Paroxetine.]
[N07BC06, heroin, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Diamorphine.]
[C04AD01, pentifylline, Levothyroxine may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Diazepam.]
[N06AA08, dibenzepin, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Dibenzepin.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Levothyroxine.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Levothyroxine.]
[L01EB02, erlotinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Erlotinib.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Levothyroxine.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Diethylstilbestrol.]
[D07XC04, diflucortolone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Difluocortolone.]
[N02BA11, diflunisal, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Diflunisal.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be decreased when it is combined with Levothyroxine.]
[C01AA05, digoxin, Levothyroxine may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AA02, polyestradiol phosphate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Polyestradiol phosphate.]
[L01XX24, pegaspargase, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Pegaspargase.]
[N02CA01, dihydroergotamine, Levothyroxine may increase the vasoconstricting activities of Dihydroergotamine.]
[J05AE08, atazanavir, The metabolism of Levothyroxine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Treprostinil can be decreased when combined with Levothyroxine.]
[C08DB01, diltiazem, The metabolism of Diltiazem can be decreased when combined with Levothyroxine.]
[R03CC08, procaterol, The risk or severity of adverse effects can be increased when Procaterol is combined with Levothyroxine.]
[N06BC02, propentofylline, Levothyroxine may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA03, proxyphylline, Levothyroxine may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA23, quinupramine, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Cisapride can be decreased when combined with Levothyroxine.]
[S01XA23, sirolimus, The serum concentration of Sirolimus can be decreased when it is combined with Levothyroxine.]
[S01AX06, resorcinol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Resorcinol.]
[C01BA03, disopyramide, The therapeutic efficacy of Disopyramide can be decreased when used in combination with Levothyroxine.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be decreased when used in combination with Levothyroxine.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be decreased when it is combined with Levothyroxine.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be decreased when it is combined with Levothyroxine.]
[S01BC05, ketorolac, The metabolism of Ketorolac can be decreased when combined with Levothyroxine.]
[C02KX02, ambrisentan, The excretion of Ambrisentan can be decreased when combined with Levothyroxine.]
[C01CA07, dobutamine, The risk or severity of adverse effects can be increased when Dobutamine is combined with Levothyroxine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Levothyroxine.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Dopamine is combined with Levothyroxine.]
[N06AA16, dothiepin, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Doxepin.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be decreased when it is combined with Levothyroxine.]
[N06AB06, sertraline, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Sertraline.]
[A08AA10, sibutramine, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Levothyroxine.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R03DA01, dyphylline, Levothyroxine may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CC01, sumatriptan, Levothyroxine may increase the vasoconstricting activities of Sumatriptan.]
[C07AB13, talinolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Talinolol.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Levothyroxine.]
[C07AA16, tertatolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Tertatolol.]
[A08AB01, orlistat, The serum concentration of Levothyroxine can be decreased when it is combined with Orlistat.]
[S01GA02, tetrahydrozoline, The risk or severity of adverse effects can be increased when Tetryzoline is combined with Levothyroxine.]
[N06AX14, tianeptine, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Tianeptine.]
[G03CX01, tibolone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Tibolone.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Levothyroxine.]
[R01AA09, tramazoline, The risk or severity of adverse effects can be increased when Tramazoline is combined with Levothyroxine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be increased when used in combination with Levothyroxine.]
[S01GA03, xylometazoline, Levothyroxine may increase the vasoconstricting activities of Xylometazoline.]
[S01EA01, epinephrine, The therapeutic efficacy of Epinephrine can be increased when used in combination with Levothyroxine.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Levothyroxine.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Levothyroxine.]
[N02CA02, ergotamine, Levothyroxine may increase the vasoconstricting activities of Ergotamine.]
[N03AG01, valproic acid, The metabolism of Levothyroxine can be decreased when combined with Valproic acid.]
[S01AA17, erythromycin, The excretion of Erythromycin can be decreased when combined with Levothyroxine.]
[A02BC02, pantoprazole, Pantoprazole can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03CA03, estradiol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Estradiol.]
[G03CC06, estriol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Estriol.]
[G03CA57, estrogens, conjugated (USP), The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Conjugated estrogens.]
[R03BA09, fluticasone furoate, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Fluticasone furoate.]
[R03BA05, fluticasone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Levothyroxine.]
[C01CA15, gepefrine, The risk or severity of adverse effects can be increased when Gepefrine is combined with Levothyroxine.]
[L02AA03, ethinyl estradiol, The metabolism of Levothyroxine can be increased when combined with Ethinylestradiol.]
[J04AD03, ethionamide, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Ethionamide.]
[N03AB01, ethotoin, The therapeutic efficacy of Ethotoin can be increased when used in combination with Levothyroxine.]
[C01CA01, etilefrine, The risk or severity of adverse effects can be increased when Etilefrine is combined with Levothyroxine.]
[L01CB01, etoposide, The serum concentration of Etoposide can be decreased when it is combined with Levothyroxine.]
[A02BA04, nizatidine, Nizatidine can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AB08, fluvoxamine, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluvoxamine.]
[C10AA03, pravastatin, The excretion of Pravastatin can be decreased when combined with Levothyroxine.]
[M01CB01, gold sodium thiomalate, The metabolism of Levothyroxine can be decreased when combined with Sodium aurothiomalate.]
[A02BA03, famotidine, Famotidine can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Levothyroxine.]
[N05CD03, flunitrazepam, The metabolism of Levothyroxine can be decreased when combined with Flunitrazepam.]
[D07AC08, fluocinonide, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Melitracen.]
[H02AB03, fluocortolone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluocortolone.]
[L01BC09, floxuridine, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Levothyroxine.]
[N06AB03, fluoxetine, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluoxetine.]
[S01BC04, flurbiprofen, The metabolism of Levothyroxine can be decreased when combined with Flurbiprofen.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Levothyroxine.]
[C03CA01, furosemide, The protein binding of Levothyroxine can be decreased when combined with Furosemide.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Levothyroxine.]
[C10AB04, gemfibrozil, The metabolism of Levothyroxine can be decreased when combined with Gemfibrozil.]
[L01EA02, dasatinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Dasatinib.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be decreased when it is combined with Levothyroxine.]
[C01CA21, cafedrine, Levothyroxine may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be decreased when used in combination with Levothyroxine.]
[A12AA13, calcium citrate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium citrate.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium lactate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium levulinate.]
[L01EH01, lapatinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Lapatinib.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be decreased when used in combination with Levothyroxine.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be decreased when used in combination with Levothyroxine.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be decreased when used in combination with Levothyroxine.]
[L01EX02, sorafenib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Sorafenib.]
[C07AB09, esmolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Esmolol.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Levothyroxine.]
[P01BX01, halofantrine, The metabolism of Halofantrine can be decreased when combined with Levothyroxine.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Levothyroxine.]
[S01XA14, heparin, The therapeutic efficacy of Heparin can be increased when used in combination with Levothyroxine.]
[A07EC02, mesalamine, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Mesalazine.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Levothyroxine.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Levothyroxine.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Levothyroxine.]
[N06AA02, imipramine, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Levothyroxine.]
[H01BA04, terlipressin, Levothyroxine may increase the vasoconstricting activities of Terlipressin.]
[L01CE01, topotecan, The serum concentration of Topotecan can be decreased when it is combined with Levothyroxine.]
[S01BC01, indomethacin, The metabolism of Levothyroxine can be decreased when combined with Indomethacin.]
[N06AX17, milnacipran, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Milnacipran.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Levothyroxine.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Levothyroxine.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Levothyroxine.]
[C07AA01, alprenolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Alprenolol.]
[N06AA13, iprindole, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Iprindole.]
[R03CB01, isoproterenol, The risk or severity of adverse effects can be increased when Isoprenaline is combined with Levothyroxine.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be decreased when used in combination with Levothyroxine.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Levothyroxine.]
[A02AB01, aluminum hydroxide, The serum concentration of Levothyroxine can be decreased when it is combined with Aluminum hydroxide.]
[N01AX03, ketamine, The risk or severity of hypertension and Tachycardia can be increased when Ketamine is combined with Levothyroxine.]
[J02AB02, ketoconazole, The metabolism of Levothyroxine can be decreased when combined with Ketoconazole.]
[V03AC03, deferasirox, The metabolism of Levothyroxine can be decreased when combined with Deferasirox.]
[C07AG01, labetalol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Labetalol.]
[N06AA07, lofepramine, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Lofepramine.]
[A07DA03, loperamide, The metabolism of Loperamide can be decreased when combined with Levothyroxine.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium pangamate.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Levothyroxine.]
[H01BA03, lypressin, Levothyroxine may increase the vasoconstricting activities of Lypressin.]
[L01EG01, temsirolimus, The serum concentration of Temsirolimus can be decreased when it is combined with Levothyroxine.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EA03, nilotinib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Nilotinib.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Levothyroxine is combined with Maprotiline.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Meclofenamic acid can be increased when used in combination with Levothyroxine.]
[C01AA08, medigoxin, Levothyroxine may increase the excretion rate of Metildigoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA11, mephentermine, The risk or severity of adverse effects can be increased when Mephentermine is combined with Levothyroxine.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Levothyroxine.]
[N05AX13, paliperidone, The serum concentration of Paliperidone can be decreased when it is combined with Levothyroxine.]
[C01CA09, metaraminol, The risk or severity of adverse effects can be increased when Metaraminol is combined with Levothyroxine.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Levothyroxine.]
[N07BC02, methadone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Methadone.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Metamfetamine is combined with Levothyroxine.]
[A03AB07, methantheline, Methantheline can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AX03, methotrexate, The excretion of Methotrexate can be decreased when combined with Levothyroxine.]
[C01CA10, methoxamine, The risk or severity of adverse effects can be increased when Methoxamine is combined with Levothyroxine.]
[R03DA05, aminophylline, Levothyroxine may increase the excretion rate of Aminophylline which could result in a lower serum level and potentially a reduction in efficacy.]
[G03EK01, methyltestosterone, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Methyltestosterone.]
[N02CA04, methysergide, Levothyroxine may increase the vasoconstricting activities of Methysergide.]
[A03FA01, metoclopramide, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Metoclopramide.]
[C07AB02, metoprolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Metoprolol.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Levothyroxine is combined with Mianserin.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Levothyroxine.]
[C01CA17, midodrine, The risk or severity of adverse effects can be increased when Midodrine is combined with Levothyroxine.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be decreased when used in combination with Levothyroxine.]
[C09CA03, valsartan, The excretion of Valsartan can be decreased when combined with Levothyroxine.]
[L01XX23, mitotane, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Levothyroxine.]
[L03AC01, aldesleukin, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Aldesleukin.]
[C01BD01, amiodarone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Amitriptyline.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Levothyroxine.]
[B02BX05, eltrombopag, The metabolism of Levothyroxine can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Pazopanib.]
[P01BA06, amodiaquine, The metabolism of Amodiaquine can be decreased when combined with Levothyroxine.]
[G03XC01, raloxifene, Raloxifene can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AA17, amoxapine, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Levothyroxine.]
[C07AA12, nadolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Nadolol.]
[S01XA11, nandrolone, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Nandrolone phenpropionate.]
[S01GA01, naphazoline, The risk or severity of adverse effects can be increased when Naphazoline is combined with Levothyroxine.]
[N06BA01, amphetamine, The risk or severity of adverse effects can be increased when Amphetamine is combined with Levothyroxine.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Levothyroxine.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be decreased when used in combination with Levothyroxine.]
[N06AX21, duloxetine, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Duloxetine.]
[L01CD02, docetaxel, The excretion of Docetaxel can be decreased when combined with Levothyroxine.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be decreased when used in combination with Levothyroxine.]
[N06AX23, desvenlafaxine, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Desvenlafaxine.]
[C10AD02, niacin, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Niacin.]
[C08CA04, nicardipine, The metabolism of Nicardipine can be decreased when combined with Levothyroxine.]
[J01XE01, nitrofurantoin, The therapeutic efficacy of Nitrofurantoin can be increased when used in combination with Levothyroxine.]
[C01CA03, norepinephrine, The therapeutic efficacy of Norepinephrine can be increased when used in combination with Levothyroxine.]
[N06AA10, nortriptyline, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Nortriptyline.]
[G02CA02, nylidrin, The risk or severity of adverse effects can be increased when Nylidrin is combined with Levothyroxine.]
[A02BC01, omeprazole, Omeprazole can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AA05, opipramol, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Opipramol.]
[R03CB03, metaproterenol, The risk or severity of adverse effects can be increased when Orciprenaline is combined with Levothyroxine.]
[H01BA05, ornipressin, Levothyroxine may increase the vasoconstricting activities of Ornipressin.]
[C01AC01, ouabain, The excretion of Ouabain can be decreased when combined with Levothyroxine.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A14AA08, oxandrolone, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Oxandrolone.]
[C07AA02, oxprenolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Oxprenolol.]
[S01GA04, oxymetazoline, The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Levothyroxine.]
[A14AA05, oxymetholone, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Oxymetholone.]
[J04AA01, aminosalicylic acid, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Aminosalicylic acid.]
[H02AB05, paramethasone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Paramethasone.]
[C07AA23, penbutolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Penbutolol.]
[C04AD03, pentoxifylline, Levothyroxine may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB03, perphenazine, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Perphenazine.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be decreased when used in combination with Levothyroxine.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Levothyroxine.]
[N03AA02, phenobarbital, The metabolism of Levothyroxine can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Levothyroxine.]
[A08AA01, phentermine, The risk or severity of adverse effects can be increased when Phentermine is combined with Levothyroxine.]
[S01GA05, phenylephrine, The risk or severity of adverse effects can be increased when Phenylephrine is combined with Levothyroxine.]
[A02BC06, dexlansoprazole, Dexlansoprazole can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R01BA01, phenylpropanolamine, The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Levothyroxine.]
[N03AB02, phenytoin, The protein binding of Levothyroxine can be decreased when combined with Phenytoin.]
[C07AA03, pindolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Levothyroxine.]
[N06BX03, piracetam, The risk or severity of confusion, irritability, and sleep disorders can be increased when Levothyroxine is combined with Piracetam.]
[S01BC06, piroxicam, The metabolism of Piroxicam can be decreased when combined with Levothyroxine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Levothyroxine.]
[D05AX05, tazarotene, The metabolism of Tazarotene can be decreased when combined with Levothyroxine.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Levothyroxine.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Levothyroxine.]
[J05AE03, ritonavir, The metabolism of Levothyroxine can be increased when combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Levothyroxine.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Levothyroxine.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Levothyroxine.]
[C07AB01, practolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Practolol.]
[H02AB07, prednisone, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Prednisone.]
[N03AA03, primidone, The metabolism of Levothyroxine can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Levothyroxine can be decreased when combined with Probenecid.]
[C01BC03, propafenone, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Propafenone.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Levothyroxine.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be decreased when it is combined with Levothyroxine.]
[N01AX10, propofol, The metabolism of Levothyroxine can be decreased when combined with Propofol.]
[C07AA05, propranolol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Propranolol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Levothyroxine.]
[N06AA11, protriptyline, The risk or severity of Cardiac Arrhythmia and CNS stimulation can be increased when Levothyroxine is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Levothyroxine.]
[C01BA01, quinidine, The serum concentration of Quinidine can be decreased when it is combined with Levothyroxine.]
[P01BC01, quinine, The therapeutic efficacy of Quinine can be decreased when used in combination with Levothyroxine.]
[A02BA02, ranitidine, Ranitidine can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J04AB02, rifampin, The metabolism of Levothyroxine can be increased when combined with Rifampicin.]
[G02CA01, ritodrine, The risk or severity of adverse effects can be increased when Ritodrine is combined with Levothyroxine.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Levothyroxine can be increased when used in combination with Salicylic acid.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Levothyroxine.]
[V04CC03, sincalide, The excretion of Sincalide can be decreased when combined with Levothyroxine.]
[C07AA07, sotalol, The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Sotalol.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be decreased when it is combined with Levothyroxine.]
